Literature DB >> 25006428

Histological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease.

Djuro Kosanovic1, Bhola Kumar Dahal1, Dorothea Maren Peters2, Michael Seimetz2, Malgorzata Wygrecka2, Katrin Hoffmann3, Jochen Antel3, Irwin Reiss4, Hossein Ardeschir Ghofrani2, Norbert Weissmann2, Friedrich Grimminger2, Werner Seeger5, Ralph Theo Schermuly2.   

Abstract

Our previous findings demonstrated an increase in pulmonary mast cells (MCs) in idiopathic pulmonary arterial hypertension (IPAH). Also, literature suggests a potential role for MCs in chronic obstructive pulmonary disease (COPD). However, a comprehensive investigation of lungs from patients is still needed. We systematically investigated the presence/expression of MCs/MC chymase in the lungs of IPAH and COPD patients by (immuno)histochemistry and subsequent quantification. We found that total and perivascular chymase-positive MCs were significantly higher in IPAH patients than in donors. In addition, chymase-positive MCs were located in proximity to regions with prominent expression of big-endothelin-1 in the pulmonary vessels of IPAH patients. Total and perivascular MCs around resistant vessels were augmented and a significant majority of them were degranulated (activated) in COPD patients. While the total chymase-positive MC count tended to increase in COPD patients, the perivascular number was significantly enhanced in all vessel sizes analyzed. Surprisingly, MC and chymase-positive MC numbers positively correlated with better lung function in COPD. Our findings suggest that activated MCs, possibly by releasing chymase, may contribute to pulmonary vascular remodeling in IPAH. Pulmonary MCs/chymase may have compartment-specific (vascular vs. airway) functions in COPD. Future studies should elucidate the mechanisms of MC accumulation and the role of MC chymase in pathologies of these severe lung diseases.

Entities:  

Keywords:  chronic obstructive pulmonary disease; chymase; idiopathic pulmonary arterial hypertension; mast cells

Year:  2014        PMID: 25006428      PMCID: PMC4070756          DOI: 10.1086/675642

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  34 in total

1.  Mast cell chymase in pulmonary hypertension.

Authors:  Y Mitani; M Ueda; K Maruyama; H Shimpo; A Kojima; M Matsumura; K Aoki; M Sakurai
Journal:  Thorax       Date:  1999-01       Impact factor: 9.139

2.  Mast cells in COPD airways: relationship to bronchodilator responsiveness and angiogenesis.

Authors:  Amir Soltani; Yean Pin Ewe; Zhen Sheng Lim; Sukhwinder S Sohal; David Reid; Steve Weston; Richard Wood-Baker; E Haydn Walters
Journal:  Eur Respir J       Date:  2011-10-27       Impact factor: 16.671

Review 3.  Mast cell peptidases: chameleons of innate immunity and host defense.

Authors:  Neil N Trivedi; George H Caughey
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-20       Impact factor: 6.914

4.  Mast cells and epsilonPKC: a role in cardiac remodeling in hypertension-induced heart failure.

Authors:  Suresh Selvaraj Palaniyandi; Koichi Inagaki; Daria Mochly-Rosen
Journal:  J Mol Cell Cardiol       Date:  2008-09-04       Impact factor: 5.000

Review 5.  Pulmonary hypertension associated with chronic obstructive pulmonary disease.

Authors:  Sunil K Chhabra
Journal:  Indian J Chest Dis Allied Sci       Date:  2010 Jan-Mar

Review 6.  Local angiotensin II-generating system in vascular tissues: the roles of chymase.

Authors:  M Miyazaki; S Takai
Journal:  Hypertens Res       Date:  2001-05       Impact factor: 3.872

7.  Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease.

Authors:  Andrea Ballarin; Erica Bazzan; Rafael Hernandez Zenteno; Graziella Turato; Simonetta Baraldo; Dora Zanovello; Elena Mutti; James C Hogg; Marina Saetta; Manuel G Cosio
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

8.  Interleukin-18 production and pulmonary function in COPD.

Authors:  H Imaoka; T Hoshino; S Takei; T Kinoshita; M Okamoto; T Kawayama; S Kato; H Iwasaki; K Watanabe; H Aizawa
Journal:  Eur Respir J       Date:  2007-11-07       Impact factor: 16.671

Review 9.  Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies.

Authors:  P D'Orléans-Juste; M Houde; G A Rae; G Bkaily; E Carrier; E Simard
Journal:  Vascul Pharmacol       Date:  2008-07-12       Impact factor: 5.773

Review 10.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

View more
  16 in total

1.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

Review 3.  Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling.

Authors:  Louis J Dell'Italia; James F Collawn; Carlos M Ferrario
Journal:  Circ Res       Date:  2018-01-19       Impact factor: 17.367

4.  A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis.

Authors:  Silvia Moretti; Giorgia Renga; Vasilis Oikonomou; Claudia Galosi; Marilena Pariano; Rossana G Iannitti; Monica Borghi; Matteo Puccetti; Marco De Zuani; Carlo E Pucillo; Giuseppe Paolicelli; Teresa Zelante; Jean-Christophe Renauld; Oxana Bereshchenko; Paolo Sportoletti; Vincenzina Lucidi; Maria Chiara Russo; Carla Colombo; Ersilia Fiscarelli; Cornelia Lass-Flörl; Fabio Majo; Gabriella Ricciotti; Helmut Ellemunter; Luigi Ratclif; Vincenzo Nicola Talesa; Valerio Napolioni; Luigina Romani
Journal:  Nat Commun       Date:  2017-01-16       Impact factor: 14.919

5.  Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension.

Authors:  Peidong Wang; Jie Yang; Yanwei Yang; Zhixin Ding
Journal:  Pak J Med Sci       Date:  2017 Mar-Apr       Impact factor: 1.088

Review 6.  Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease.

Authors:  Tapan Dey; Jatin Kalita; Sinéad Weldon; Clifford C Taggart
Journal:  J Clin Med       Date:  2018-08-28       Impact factor: 4.241

7.  New dynamic viewing of mast cells in pulmonary arterial hypertension (PAH): contributors or outsiders to cardiovascular remodeling.

Authors:  Jian Xu; Jingjing Wang; Chengjie Shao; Xiaoning Zeng; Lixiang Sun; Hui Kong; Weiping Xie; Hong Wang
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

8.  An Optimized Protocol for the Isolation and Functional Analysis of Human Lung Mast Cells.

Authors:  Avinash Ravindran; Elin Rönnberg; Joakim S Dahlin; Luca Mazzurana; Jesper Säfholm; Ann-Charlotte Orre; Mamdoh Al-Ameri; Peter Peachell; Mikael Adner; Sven-Erik Dahlén; Jenny Mjösberg; Gunnar Nilsson
Journal:  Front Immunol       Date:  2018-10-05       Impact factor: 7.561

9.  Yarsagumba is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties.

Authors:  Himal Luitel; Tatyana Novoyatleva; Akylbek Sydykov; Aleksandar Petrovic; Argen Mamazhakypov; Bhuminand Devkota; Malgorzata Wygrecka; Hossein Ardeschir Ghofrani; Sergey Avdeev; Ralph Theo Schermuly; Djuro Kosanovic
Journal:  Medicina (Kaunas)       Date:  2020-03-16       Impact factor: 2.430

Review 10.  Role of inflammatory cells in airway remodeling in COPD.

Authors:  Yujie Wang; Jiayan Xu; Yaqi Meng; Ian M Adcock; Xin Yao
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.